<?xml version="1.0" encoding="UTF-8"?>
<p id="p0020">An ongoing clinical trial of convenience, WARRIOR, with projected enrollment of 4422 women with symptoms and signs of ischemia but no obstructive coronary artery disease is randomly assigning participants to either usual care or intensive medical treatment (IMT) consisting of high dose ACE-I (or ARB), high potency statin, and low-dose aspirin. Currently ~1000 women are enrolled and available for COVID-19 investigation, at 50 sites across the US.</p>
